Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVONASDAQ:ATXINYSE:BONNASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$0.67-2.4%$1.94$0.60▼$51.06$985K5.75848,842 shs410,799 shsATXIAvenue Therapeutics$0.25+0.8%$0.60$0.23▼$5.97$794K0.1141,995 shs26,263 shsBONBon Natural Life$0.06-6.8%$0.44$0.05▼$5.31$239K-0.517.05 million shs9.02 million shsWINTWindtree Therapeutics$1.21+3.4%$1.94$1.01▼$737.44$906K0.91736,211 shs86,084 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics0.00%-21.71%-39.75%-84.97%-99.93%ATXIAvenue Therapeutics0.00%-4.94%-18.97%-83.20%-95.94%BONBon Natural Life0.00%0.00%-50.52%-95.96%-98.66%WINTWindtree Therapeutics0.00%+6.14%-22.44%-84.71%-99.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPVOAptevo Therapeutics2.2635 of 5 stars3.52.00.00.03.00.01.3ATXIAvenue Therapeutics2.3071 of 5 stars0.05.00.04.61.10.01.9BONBon Natural LifeN/AN/AN/AN/AN/AN/AN/AN/AWINTWindtree Therapeutics2.2575 of 5 stars3.04.00.00.02.50.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 3.00Buy$10,952.001,622,899.41% UpsideATXIAvenue Therapeutics 0.00N/AN/AN/ABONBon Natural Life 0.00N/AN/AN/AWINTWindtree Therapeutics 2.00Hold$350.0028,825.62% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo Therapeutics$3.11M0.32N/AN/A$3.26 per share0.21ATXIAvenue TherapeuticsN/AN/AN/AN/A$1.92 per shareN/ABONBon Natural Life$23.84M0.01$0.07 per share0.78$37.78 per share0.00WINTWindtree TherapeuticsN/AN/AN/AN/A$10.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-488.93%-152.51%5/6/2025 (Estimated)ATXIAvenue Therapeutics-$10.38M$18.350.01∞N/AN/A-471.57%-296.50%5/13/2025 (Estimated)BONBon Natural Life$400KN/A0.00∞N/AN/AN/AN/AN/AWINTWindtree Therapeutics-$20.29M-$823.47N/AN/AN/AN/A-362.76%-79.65%5/21/2025 (Estimated)Latest BON, APVO, WINT, and ATXI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025N/AWINTWindtree Therapeutics-$39.00N/AN/AN/AN/AN/A5/14/2025N/AAPVOAptevo Therapeutics-$4.21N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AATXIAvenue TherapeuticsN/AN/AN/AN/AN/ABONBon Natural LifeN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A1.721.72ATXIAvenue TherapeuticsN/A2.702.70BONBon Natural Life0.022.422.32WINTWindtree TherapeuticsN/A0.270.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%ATXIAvenue Therapeutics17.34%BONBon Natural Life0.57%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.12%ATXIAvenue Therapeutics1.80%BONBon Natural Life26.48%WINTWindtree Therapeutics0.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics501.46 million1.46 millionNot OptionableATXIAvenue Therapeutics43.15 million2.02 millionNot OptionableBONBon Natural Life1004.17 million863,000Not OptionableWINTWindtree Therapeutics30749,00011.01 millionNot OptionableBON, APVO, WINT, and ATXI HeadlinesRecent News About These CompaniesWindtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business UpdatesApril 15, 2025 | markets.businessinsider.comEvofem announces license and supply agreement with Windtree TherapeuticsMarch 27, 2025 | markets.businessinsider.comEvofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree TherapeuticsMarch 26, 2025 | prnewswire.comWindtree Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementMarch 24, 2025 | quiverquant.comWindtree Therapeutics Regains Compliance with Nasdaq Listing RulesMarch 24, 2025 | globenewswire.comWindtree Therapeutics (NASDAQ:WINT) Stock, Insider Trading ActivityMarch 21, 2025 | benzinga.comWindtree to become sourcing partner for Evofem BiosciencesMarch 21, 2025 | markets.businessinsider.comWindtree Therapeutics and Evofem Announce Agreement to Lower Manufacturing Costs for PHEXXI®March 21, 2025 | msn.comAnother Day, Another Biotech Ripping Before The BellMarch 20, 2025 | msn.comWindtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved ProductMarch 20, 2025 | globenewswire.comWINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating CoverageMarch 4, 2025 | msn.comWindtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart FailureMarch 4, 2025 | markets.businessinsider.comWindtree Therapeutics announces notice of allowance from USPTO for istaroximeMarch 4, 2025 | markets.businessinsider.comWindtree Therapeutics Files Patent Application in India for Istaroxime, Advancing Arrhythmia TreatmentMarch 2, 2025 | msn.comWindtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for IndiaFebruary 27, 2025 | markets.businessinsider.comWindtree Therapeutics files patent in India for cardiac arrythmia therapyFebruary 27, 2025 | markets.businessinsider.comWindtree Therapeutics Inc trading halted, news pendingFebruary 20, 2025 | markets.businessinsider.comWindtree Therapeutics board approves 1-for-50 reverse stock splitFebruary 19, 2025 | markets.businessinsider.comWindtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq ComplianceFebruary 18, 2025 | msn.comWindtree Therapeutics, Inc. Announces Reverse Stock SplitFebruary 18, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Buffett’s Next Oil Bet: Why Occidental Is DifferentBy Jea Yu | April 8, 2025View Buffett’s Next Oil Bet: Why Occidental Is DifferentBuffett’s $150B Bond Move: What It Really Means for InvestorsBy Gabriel Osorio-Mazilli | April 7, 2025View Buffett’s $150B Bond Move: What It Really Means for Investors3 Bond ETFs for the Diversified InvestorBy Chris Markoch | April 13, 2025View 3 Bond ETFs for the Diversified InvestorBuffett Loves Occidental Petroleum—Should You? 4 Pros, 3 ConsBy Jea Yu | April 15, 2025View Buffett Loves Occidental Petroleum—Should You? 4 Pros, 3 ConsBON, APVO, WINT, and ATXI Company DescriptionsAptevo Therapeutics NASDAQ:APVO$0.67 -0.02 (-2.43%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.66 -0.02 (-2.34%) As of 04/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Avenue Therapeutics NASDAQ:ATXI$0.25 +0.00 (+0.76%) As of 04/25/2025 01:27 PM EasternAvenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.Bon Natural Life NYSE:BON$0.06 0.00 (-6.82%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.06 +0.00 (+4.53%) As of 04/25/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.Windtree Therapeutics NASDAQ:WINT$1.21 +0.04 (+3.42%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.22 +0.01 (+1.16%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/21 - 04/25 Bears Can Reap Big Benefits With These 3 Short ETF Bets If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? Markets Think Robinhood Earnings Could Send the Stock Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
